TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07867171: A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of Velzatinib in Participants With Moderate or Severe Renal Impairment Compared to Healthy Participants

Sponsor: GlaxoSmithKline · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07867171 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07867171 Rescue Dossier →